Insights from 2023 ASH Annual Meeting

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Insights from 2023 ASH Annual Meeting

Lymphoma
Leukemia
Myeloma
MDS and MPN
Benign Hematology
Videos

Playback speed

10 seconds

ASH 2023 Insights: "FREEDOM2 Study of Fedratinib in Patients With MF Previously Treated With Ruxolitinib"

By Insights from 2023 ASH Annual Meeting FEATURING Claire Harrison

90 views

December 17, 2023

Comments 0

Moving Forward in Stage III/IV Classical Hodgkin Lymphoma

Feat. A. Ip

The First Treatment Choice Matters

Feat. A. Ip

MDS and MPN

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Implicat…

Insights from 2023 ASH Annual Meeting

D. Tremblay

407 views

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

R. Mesa

364 views

ASH 2023 Insights: "LIMBER-103 Study - BETi INCB057643 in Pts With R…

Insights from 2023 ASH Annual Meeting

J. Watts

49 views

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

928 views

ASH 2023 Insights: "Study of Add-on Therapy With CK0804 in Patients …

Insights from 2023 ASH Annual Meeting

L. Masarova

29 views

ASH 2023 Insights: "PIM1 Kinase Inhibitor TP-3654 for R/R Myelofibro…

Insights from 2023 ASH Annual Meeting

L. Rein

37 views

ASH 2023 Insights: "Validation of the Composite CR Definitions in th…

Insights from 2023 ASH Annual Meeting

J. Bewersdorf

108 views

ASH 2023 Insights: "MATTERHORN Study - Efficacy & Safety of Roxadust…

Insights from 2023 ASH Annual Meeting

M. Mittelman

68 views

ASH 2023 Insights: "Guadecitabine in Higher-Risk MDS and CMML Under …

Insights from 2023 ASH Annual Meeting

S. Urrutia

63 views

ASH 2023 Insights: "FREEDOM2 Study of Fedratinib in Patients With MF…

Insights from 2023 ASH Annual Meeting

C. Harrison

90 views

ASH 2023 Insights: "Durable Clinical Benefit With KER-050 (Elriterce…

Insights from 2023 ASH Annual Meeting

M. Diez-Campelo

31 views

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Insights from 2023 ASH Annual Meeting

D. Tremblay

433 views